{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:43:00Z","timestamp":1778604180236,"version":"3.51.4"},"reference-count":60,"publisher":"American Association for Cancer Research (AACR)","issue":"21","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA237272"],"award-info":[{"award-number":["CA237272"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA233562"],"award-info":[{"award-number":["CA233562"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Assistant Secretary of Defense for Health Affairs","award":["W81XWH-17-1-0275"],"award-info":[{"award-number":["W81XWH-17-1-0275"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The retrotransposon-derived paternally expressed gene 10 (PEG10) protein is ordinarily expressed at high levels in the placenta. Recently, it was discovered that PEG10 isoforms promote the progression of prostate cancer to a highly lethal androgen receptor (AR)-negative phenotype. The presence of PEG10 in other subtypes of prostate cancer has not been explored and a utility for PEG10 overexpression has not been developed. Here, we found that in addition to AR-null disease, PEG10 was also expressed in prostate cancer with constitutively active AR-splice variants. A molecular genetic imaging strategy for noninvasive imaging of AR-splice variant prostate cancer was developed by utilizing the cancer specificity of the PEG10 promoter to drive the expression of reporter genes. Plasmid insertion of a PEG10 promoter sequence optimized for enhanced output upstream of a reporter gene allowed detection of prostate cancer by near-infrared and positron emission tomography imaging after systemic administration of the plasmid in vivo. PEG10 expressing subcutaneous xenograft and intratibial tumor models were imaged by both modalities using this molecular genetic imaging strategy. This study demonstrates a preclinical proof-of-concept that the PEG10 promoter is a powerful and specific tool that can be utilized for noninvasive detection of aggressive prostate cancer subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>PEG10 is expressed by prostate cancer with constitutively active AR-splice variants that can be exploited for noninvasive molecular imaging of this aggressive prostate cancer subytpe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-19-2181","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T14:05:18Z","timestamp":1568729118000},"page":"5668-5680","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["PEG10 Promoter\u2013Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer"],"prefix":"10.1158","volume":"79","author":[{"given":"Mariya","family":"Shapovalova","sequence":"first","affiliation":[{"name":"1Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Lee","sequence":"additional","affiliation":[{"name":"2Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingming","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine and Pathology, Department of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-5698","authenticated-orcid":false,"given":"Donald J.","family":"Vander Griend","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine and Pathology, Department of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilsa M.","family":"Coleman","sequence":"additional","affiliation":[{"name":"2Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"2Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-5579","authenticated-orcid":false,"given":"Scott M.","family":"Dehm","sequence":"additional","affiliation":[{"name":"4Department of Pathology, University of Illinois at Chicago, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"LeBeau","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"2022061706362639300_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2022061706362639300_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"2022061706362639300_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CCO.0b013e32835105b3","article-title":"The androgen\/androgen receptor axis in prostate cancer","volume":"24","author":"Bluemn","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2022061706362639300_bib4","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1210\/en.2013-1466","article-title":"Mechanisms of androgen receptor activation in castration-resistant prostate cancer","volume":"154","author":"Sharifi","year":"2013","journal-title":"Endocrinology"},{"key":"2022061706362639300_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9060067","article-title":"Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance","volume":"9","author":"D. Crona","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2022061706362639300_bib6","first-page":"15","article-title":"Anti-androgen therapies for prostate cancer: a focused review","volume-title":"Am J Hematol Oncol","author":"Ammannagari","year":"2015"},{"key":"2022061706362639300_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2022061706362639300_bib8","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706362639300_bib9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2214\/AJR.09.2579","article-title":"Challenges in clinical prostate cancer: role of imaging","volume":"192","author":"Kelloff","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"2022061706362639300_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.semnuclmed.2016.07.003","article-title":"(18)F-NaF-PET\/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer","volume":"46","author":"Langsteger","year":"2016","journal-title":"Semin Nucl Med"},{"key":"2022061706362639300_bib11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jamaoncol.2016.5840","article-title":"Imaging locally advanced, recurrent, and metastatic prostate cancer: a review","volume":"3","author":"Lindenberg","year":"2017","journal-title":"JAMA Oncol"},{"key":"2022061706362639300_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2022061706362639300_bib13","doi-asserted-by":"crossref","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706362639300_bib14","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","article-title":"Correlation of PSMA-targeted (18)F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer","volume":"15","author":"Tosoian","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2022061706362639300_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/B978-0-12-411638-2.00004-5","article-title":"Molecular-genetic imaging of cancer","volume":"124","author":"Minn","year":"2014","journal-title":"Adv Cancer Res"},{"key":"2022061706362639300_bib16","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/0008-5472.CAN-14-0018","article-title":"AEG-1 promoter-mediated imaging of prostate cancer","volume":"74","author":"Bhatnagar","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706362639300_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nm.2269","article-title":"Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression","volume":"17","author":"Bhang","year":"2011","journal-title":"Nat Med"},{"key":"2022061706362639300_bib18","article-title":"Suicide gene therapy for cancer - current strategies","volume":"4","author":"Zarogoulidis","year":"2013","journal-title":"J Genet Syndr Gene Ther"},{"key":"2022061706362639300_bib19","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2013.12.011","article-title":"DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer","volume":"191","author":"Gofrit","year":"2014","journal-title":"J Urol"},{"key":"2022061706362639300_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10072-006-0679-7","article-title":"Two novel Italian CADASIL families from Central Italy with mutation CGC-TGC at codon 1006 in the exon 19 Notch3 gene","volume":"27","author":"Ragno","year":"2006","journal-title":"Neurol Sci"},{"key":"2022061706362639300_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","article-title":"The placental gene PEG10 promotes progression of neuroendocrine prostate cancer","volume":"12","author":"Akamatsu","year":"2015","journal-title":"Cell Rep"},{"key":"2022061706362639300_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ng1699","article-title":"Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality","volume":"38","author":"Ono","year":"2006","journal-title":"Nat Genet"},{"key":"2022061706362639300_bib23","doi-asserted-by":"crossref","first-page":"17492","DOI":"10.1073\/pnas.1308587110","article-title":"TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer","volume":"110","author":"Nyquist","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706362639300_bib24","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/1078-0432.CCR-17-3673","article-title":"MEIS1 and MEIS2 expression and prostate cancer progression: a role for HOXB13 binding partners in metastatic disease","volume":"24","author":"Bhanvadia","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022061706362639300_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"2022061706362639300_bib26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pros.23313","article-title":"LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics","volume":"77","author":"Nguyen","year":"2017","journal-title":"Prostate"},{"key":"2022061706362639300_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0166-0934(03)00069-7","article-title":"Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene","volume":"109","author":"Ebeling","year":"2003","journal-title":"J Virol Methods"},{"key":"2022061706362639300_bib28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"2022061706362639300_bib29","doi-asserted-by":"crossref","first-page":"e8686","DOI":"10.1371\/journal.pone.0008686","article-title":"Genetic and molecular analyses of PEG10 reveal new aspects of genomic organization, transcription and translation","volume":"5","author":"Lux","year":"2010","journal-title":"PLoS One"},{"key":"2022061706362639300_bib30","doi-asserted-by":"crossref","first-page":"14595","DOI":"10.1073\/pnas.251551098","article-title":"Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters","volume":"98","author":"Iyer","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706362639300_bib31","first-page":"769","article-title":"Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging","volume":"26","author":"Watanabe","year":"2011","journal-title":"Oncol Rep"},{"key":"2022061706362639300_bib32","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1101\/gad.2.6.718","article-title":"Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression","volume":"2","author":"Triezenberg","year":"1988","journal-title":"Genes Dev"},{"key":"2022061706362639300_bib33","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1002\/j.1460-2075.1992.tb05607.x","article-title":"A synergistic increase in potency of a multimerized VP16 transcriptional activation domain","volume":"11","author":"Emami","year":"1992","journal-title":"EMBO J"},{"key":"2022061706362639300_bib34","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1242\/dev.128.13.2593","article-title":"A UAS site substitution approach to the in vivo dissection of promoters: interplay between the GATAb activator and the AEF-1 repressor at a Drosophila ecdysone response unit","volume":"128","author":"Brodu","year":"2001","journal-title":"Development"},{"key":"2022061706362639300_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1101\/gr.110684.110","article-title":"Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing","volume":"21","author":"Pflueger","year":"2011","journal-title":"Genome Res"},{"key":"2022061706362639300_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2022061706362639300_bib37","doi-asserted-by":"crossref","first-page":"18550","DOI":"10.18632\/oncotarget.14537","article-title":"Androgen receptor splice variants and prostate cancer: from bench to bedside","volume":"8","author":"Wadosky","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706362639300_bib38","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res"},{"key":"2022061706362639300_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res"},{"key":"2022061706362639300_bib40","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-16-0718","article-title":"BIRC6 targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer","volume":"23","author":"Luk","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706362639300_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"2022061706362639300_bib42","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","article-title":"Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance","volume":"23","author":"Kohli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706362639300_bib43","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat Med"},{"key":"2022061706362639300_bib44","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat Commun"},{"key":"2022061706362639300_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/mthe.2002.0551","article-title":"Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer","volume":"5","author":"Zhang","year":"2002","journal-title":"Mol Ther"},{"key":"2022061706362639300_bib46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nmeth.2521","article-title":"Near-infrared fluorescent proteins for multicolor in vivo imaging","volume":"10","author":"Shcherbakova","year":"2013","journal-title":"Nat Methods"},{"key":"2022061706362639300_bib47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pros.10091","article-title":"Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells","volume":"52","author":"Corey","year":"2002","journal-title":"Prostate"},{"key":"2022061706362639300_bib48","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1038\/nprot.2006.459","article-title":"PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG","volume":"1","author":"Yaghoubi","year":"2006","journal-title":"Nat Protoc"},{"key":"2022061706362639300_bib49","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1038\/nprot.2006.334","article-title":"Measuring herpes simplex virus thymidine kinase reporter gene expression in vitro","volume":"1","author":"Yaghoubi","year":"2006","journal-title":"Nat Protoc"},{"key":"2022061706362639300_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40336-016-0186-7","article-title":"The role of iodine-124 positron emission tomography in molecular imaging","volume":"4","author":"Mahajan","year":"2016","journal-title":"Clinical and Translational Imaging"},{"key":"2022061706362639300_bib51","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1073\/pnas.0408861102","article-title":"Imaging bacterial infections with radiolabeled 1-(2\u2032-deoxy-2\u2032-fluoro-beta-D-arabinofuranosyl)-5-iodouracil","volume":"102","author":"Bettegowda","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706362639300_bib52","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/gt.2010.63","article-title":"A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer","volume":"17","author":"Trujillo","year":"2010","journal-title":"Gene Ther"},{"key":"2022061706362639300_bib53","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/0008-5472.CAN-11-1520","article-title":"Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer","volume":"71","author":"Jiang","year":"2011","journal-title":"Cancer Res"},{"key":"2022061706362639300_bib54","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nm.1727","article-title":"Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer","volume":"14","author":"Burton","year":"2008","journal-title":"Nat Med"},{"key":"2022061706362639300_bib55","doi-asserted-by":"crossref","first-page":"36693","DOI":"10.18632\/oncotarget.26401","article-title":"Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer","volume":"9","author":"Shapovalova","year":"2018","journal-title":"Oncotarget"},{"key":"2022061706362639300_bib56","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/mt.2015.1","article-title":"First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings","volume":"23","author":"Buscail","year":"2015","journal-title":"Mol Ther"},{"key":"2022061706362639300_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/cgt.2012.10","article-title":"Phase 1\/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer","volume":"19","author":"Hanna","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"2022061706362639300_bib58","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00404-017-4293-0","article-title":"A phase 1\/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian\/peritoneal cancer","volume":"295","author":"Lavie","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"2022061706362639300_bib59","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1158\/1078-0432.CCR-14-0169","article-title":"Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer","volume":"20","author":"McNeel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706362639300_bib60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jgm.237","article-title":"Side-effects of a systemic injection of linear polyethylenimine-DNA complexes","volume":"4","author":"Chollet","year":"2002","journal-title":"J Gene Med"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/21\/5668\/2871448\/5668.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/21\/5668\/2871448\/5668.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:08:56Z","timestamp":1655482136000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/79\/21\/5668\/657612\/PEG10-Promoter-Driven-Expression-of-Reporter-Genes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":60,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-2181","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6512233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426120","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512233.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426120.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}